<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
    <channel>
        <title>MoFo Life Sciences</title>
        <link>https://lifesciences.mofo.com/</link>
        <description>Keeping pace with the ever-changing life sciences industry, Morrison Foerster stays on top of the trends and political, legal, and economic drivers to support striking the balance between innovative discovery and purposeful business planning to assure our clients continued success. MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.Learn more about our Life Sciences practice.ABOUT MORRISON FOERSTERMorrison Foerster is a leading global law firm that transforms complexity into advantage for its clients. Our clients include some of the largest financial institutions, banks, consulting and accounting firms, and Fortune 100, technology, and life sciences companies. Highlighting the firm’s commitment to client service, leadership in market-changing deals and impact litigation, and values-based culture, Morrison Foerster has been repeatedly recognized as one of the top 10 firms on The American Lawyer’s A-List. Year after year, the firm receives significant recognition from Chambers and The Legal 500 across their various guides, including Global, USA, Asia‑Pacific, Europe, UK, Latin America, and FinTech Legal. Our lawyers passionately care about delivering legal excellence while living our values. Morrison Foerster has a long-standing commitment to creating a culture that respects and celebrates differences, while providing an inclusive environment. The firm also has a long history of commitment to the community and society through providing pro bono legal services, including litigating for civil rights and civil liberties, improving public education and fostering the wellbeing of children, advocating for veterans, promoting international human rights, enforcing the right to asylum, and safeguarding the environment.</description>
        <lastBuildDate>Thu, 14 May 2026 23:07:35 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>Morrison Foerster RSS Generator</generator>
        <image>
            <title>MoFo Life Sciences</title>
            <url>https://media2.mofo.com/v3/assets/blt5775cc69c999c255/blt8906897ee1aa88fc/6283182abd980555189d32df/apple-touch-icon.png</url>
            <link>https://lifesciences.mofo.com/</link>
        </image>
        <copyright>All rights reserved Morrison Foerster LLP. All Rights Reserved.</copyright>
        <item>
            <title><![CDATA[CMS Announces Pause on Home Health and Hospice Enrollments amid Expanding Fraud Crackdown]]></title>
            <link>https://lifesciences.mofo.com//topics/cms-announces-pause-on-home-health-and-hospice-enrollments-amid-expanding-fraud-crackdown</link>
            <guid>https://lifesciences.mofo.com//topics/cms-announces-pause-on-home-health-and-hospice-enrollments-amid-expanding-fraud-crackdown</guid>
            <pubDate>Thu, 14 May 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[New Coverage Pathway for Medical Devices]]></title>
            <link>https://lifesciences.mofo.com//topics/new-coverage-pathway-for-medical-devices</link>
            <guid>https://lifesciences.mofo.com//topics/new-coverage-pathway-for-medical-devices</guid>
            <pubDate>Wed, 29 Apr 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[FDA’s Revised Biosimilar Q&As: Three Things Sponsors Should Know]]></title>
            <link>https://lifesciences.mofo.com//topics/fda-s-revised-biosimilar-q-as-three-things-sponsors-should-know</link>
            <guid>https://lifesciences.mofo.com//topics/fda-s-revised-biosimilar-q-as-three-things-sponsors-should-know</guid>
            <pubDate>Tue, 17 Mar 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[USDA APHIS BRS Promises Continued Efficiency]]></title>
            <link>https://lifesciences.mofo.com//topics/usda-aphis-brs-promises-continued-efficiency</link>
            <guid>https://lifesciences.mofo.com//topics/usda-aphis-brs-promises-continued-efficiency</guid>
            <pubDate>Wed, 11 Mar 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Three Things to Know About FDA’s “Plausible Mechanism” Guidance]]></title>
            <link>https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-plausible-mechanism-guidance</link>
            <guid>https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-plausible-mechanism-guidance</guid>
            <pubDate>Thu, 26 Feb 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Recombinant Host Cells Are Patent-eligible: Federal Circuit Revives Regenxbio’s Gene Delivery Patent]]></title>
            <link>https://lifesciences.mofo.com//topics/recombinant-host-cells-are-patent-eligible-federal-circuit-revives-regenxbio-s-gene-delivery-patent</link>
            <guid>https://lifesciences.mofo.com//topics/recombinant-host-cells-are-patent-eligible-federal-circuit-revives-regenxbio-s-gene-delivery-patent</guid>
            <pubDate>Mon, 23 Feb 2026 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Texas SB 25 Litigation: Trade Associations Challenge TX Warning Label Requirement]]></title>
            <link>https://lifesciences.mofo.com//topics/texas-sb-25-litigation-trade-associations-challenge-tx-warning-label-requirement</link>
            <guid>https://lifesciences.mofo.com//topics/texas-sb-25-litigation-trade-associations-challenge-tx-warning-label-requirement</guid>
            <pubDate>Thu, 11 Dec 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Blaze Marks and Written Description: Patent Drafting Lessons from Duke v. Sandoz]]></title>
            <link>https://lifesciences.mofo.com//topics/blaze-marks-written-description-patent-drafting-lessons-duke-v-sandoz</link>
            <guid>https://lifesciences.mofo.com//topics/blaze-marks-written-description-patent-drafting-lessons-duke-v-sandoz</guid>
            <pubDate>Wed, 10 Dec 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Strategic Filing of AI and Life Sciences Software]]></title>
            <link>https://lifesciences.mofo.com//topics/strategic-filing-of-ai-and-life-sciences-software</link>
            <guid>https://lifesciences.mofo.com//topics/strategic-filing-of-ai-and-life-sciences-software</guid>
            <pubDate>Tue, 09 Dec 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Europe’s New Genomic Techniques: Patent Ban Off the Table]]></title>
            <link>https://lifesciences.mofo.com//topics/europe-s-new-genomic-techniques-patent-ban-off-the-table</link>
            <guid>https://lifesciences.mofo.com//topics/europe-s-new-genomic-techniques-patent-ban-off-the-table</guid>
            <pubDate>Mon, 08 Dec 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[It’s Baaack… The BIOSECURE Act Passes Senate]]></title>
            <link>https://lifesciences.mofo.com//topics/251024-biosecure-act-passes-senate</link>
            <guid>https://lifesciences.mofo.com//topics/251024-biosecure-act-passes-senate</guid>
            <pubDate>Fri, 24 Oct 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Three Things to Know about FDA’s Newest Draft Guidance on Cell & Gene Therapies]]></title>
            <link>https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-newest-draft-guidance-on-cell-gene-therapies</link>
            <guid>https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-newest-draft-guidance-on-cell-gene-therapies</guid>
            <pubDate>Thu, 23 Oct 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Another Step Change for USDA’s GE Regs: APHIS Ceases NEPA Review of Petitions for Nonregulated Status]]></title>
            <link>https://lifesciences.mofo.com//topics/another-step-change-for-usda-s-ge-regs-aphis-ceases-nepa-review-of-petitions-for-nonregulated-status</link>
            <guid>https://lifesciences.mofo.com//topics/another-step-change-for-usda-s-ge-regs-aphis-ceases-nepa-review-of-petitions-for-nonregulated-status</guid>
            <pubDate>Fri, 25 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Key Developments in MedTech M&A: Momentum Despite Macroeconomic Uncertainty]]></title>
            <link>https://lifesciences.mofo.com//topics/key-developments-in-medtech-m-a-momentum-despite-macroeconomic-uncertainty</link>
            <guid>https://lifesciences.mofo.com//topics/key-developments-in-medtech-m-a-momentum-despite-macroeconomic-uncertainty</guid>
            <pubDate>Mon, 14 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Is Your Claim Open or Closed? Claim Construction Takes on a New Meaning in Eye Therapies, LLC v. Slayback Pharma, LLC]]></title>
            <link>https://lifesciences.mofo.com//topics/is-your-claim-open-or-closed-claim-construction-takes-on-a-new-meaning-in-eye-therapies-llc-v-slayback-pharma-llc</link>
            <guid>https://lifesciences.mofo.com//topics/is-your-claim-open-or-closed-claim-construction-takes-on-a-new-meaning-in-eye-therapies-llc-v-slayback-pharma-llc</guid>
            <pubDate>Thu, 10 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Need to FAST Track Your Patent? The USPTO increases the Annual Limit to 20,000]]></title>
            <link>https://lifesciences.mofo.com//topics/need-to-fast-track-your-patent-the-uspto-increases-the-annual-limit-to-20-000</link>
            <guid>https://lifesciences.mofo.com//topics/need-to-fast-track-your-patent-the-uspto-increases-the-annual-limit-to-20-000</guid>
            <pubDate>Wed, 09 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[What Makes a Good Cell and Gene Therapy Application?]]></title>
            <link>https://lifesciences.mofo.com//topics/what-makes-a-good-cell-and-gene-therapy-application-</link>
            <guid>https://lifesciences.mofo.com//topics/what-makes-a-good-cell-and-gene-therapy-application-</guid>
            <pubDate>Tue, 08 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[A Tip for Improving Your “Improved” Jepson Claim: Include Written Description Support]]></title>
            <link>https://lifesciences.mofo.com//topics/a-tip-for-improving-your-improved-jepson-claim-include-written-description-support</link>
            <guid>https://lifesciences.mofo.com//topics/a-tip-for-improving-your-improved-jepson-claim-include-written-description-support</guid>
            <pubDate>Mon, 07 Jul 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[USPTO Discontinues Accelerated Examination Program in Favor of Expanding Track One Program]]></title>
            <link>https://lifesciences.mofo.com//topics/uspto-discontinues-accelerated-examination-program-in-favor-of-expanding-track-one-program</link>
            <guid>https://lifesciences.mofo.com//topics/uspto-discontinues-accelerated-examination-program-in-favor-of-expanding-track-one-program</guid>
            <pubDate>Tue, 10 Jun 2025 00:00:00 GMT</pubDate>
        </item>
        <item>
            <title><![CDATA[Subject Matter Eligibility of AI Medical Treatments]]></title>
            <link>https://lifesciences.mofo.com//topics/sm-eligibility-of-ai-medical-treatments</link>
            <guid>https://lifesciences.mofo.com//topics/sm-eligibility-of-ai-medical-treatments</guid>
            <pubDate>Tue, 03 Jun 2025 00:00:00 GMT</pubDate>
        </item>
    </channel>
</rss>